About Seer
Seer is a publicly listed company based in San Francisco (United States) founded in 2017. It operates as a proteomics platform developed for early cancer and neurological disease detection. It operates on a Product-as-a-Service and HealthTech model. Seer has raised $127.5 million across 7 funding rounds from investors including Fidelity Investments, T. Rowe Price and Bruker. The company has 134 employees. Its website seer.bio draws about 16 thousand monthly visits. Seer offers products and services including Proteograph Product Suite, Proteograph Analysis Suite, and Seer Technology Access Center. Its focus areas include Biotechnology and Proteomics. Its legal entity is Seer, Inc. Its competitors include Metabolon, Cyrus Biotechnology, Maze Therapeutics, Vividion Therapeutics and Alector and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Seer, Inc. is dedicated to pioneering innovative technologies for proteomics research. The company is engaged in developing tools like the Proteograph Product Suite to enable deep, rapid, and unbiased proteomics at scale. Solutions such as the Proteograph Analysis Suite are provided for efficient data analysis. Operating in the healthcare and biotechnology sectors, Seer aims to eliminate barriers in proteomics, empowering the scientific community to achieve exceptional outcomes. Their technology is utilized by top researchers and featured in numerous scientific publications. The mission is centered on decoding the proteome to improve human health globally.
- Annual Revenue$16.12 M (USD)15.57as on Dec 31, 2025
- Net Profit-$73.6 M (USD)15.01as on Dec 31, 2025
- EBITDA-$72.35 M (USD)23.16as on Dec 31, 2025
- Total Equity Funding$127.5M (USD)
in 7 rounds
- Latest Funding Round$55M (USD), Series D
Jul 2020
- InvestorsFidelity Investments
& 10 more
- Employee Count134
Products & Services of Seer
Seer offers a comprehensive portfolio of products and services, including Proteograph Product Suite, Proteograph Analysis Suite, and Seer Technology Access Center.
Deep, rapid, unbiased proteomics analysis at scale provided.
Proteomics data is analyzed quickly and easily here.
White-glove service programs for proteomics are offered now.
Apps and channels of Seer
its YouTube channel Seer Inc. has 421 subscribers and 30 videos.
Videos from Seer
The most watched videos on Seer's YouTube channel, Seer Inc. (421 subscribers). Click a video to play it here.
More on Seer Inc..
Funding Insights of Seer
Seer has successfully raised a total of $127.5M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $55 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $127.5M
- Total Rounds 7
- Last Round Series D — $55M
- First Round $150,000
(Jan 2017)
- Investors Count 11
All 7 funding rounds of Seer with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $55M | Series D | – | Fidelity Investments, aMoon | |
| Dec 2019 | $55M | Series D | – | aMoon | |
| Sep 2019 | $2.04M | Grant | – | – | |
| Jul 2019 | $17.5M | Series C | – | Wing Venture Capital, Aju IB Investment | |
| Jun 2018 | – | Series B | – | Invus | – |
| Jun 2017 | – | Series A | – | Maverick Ventures | – |
| Jan 2017 | $150,000 | Grant | – | – |
11 investors in total: 11 institutional.
Investors in Seer
Seer has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Bruker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Venture capital investments in healthcare are focused on by aMoon. | – | amoon.fund | - | |
Venture capital fund and fund of funds focused on early-stage startups | – | wing.vc | Palo Alto, United States | |
Early-stage tech and life-sciences firms are funded across the US. | – | maverickventures.com | San Francisco, United States | |
Diversified investment, VC & financial advisory firm | 1974 | ajuib.co.kr | Seoul, South Korea | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Diversified research instrument systems are manufactured and supplied. | 1960 | bruker.com | United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
- | – | emersoncollective.com | - |
Investor details for Seer
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Seer
69 people are tracked at Seer (25 in leadership, 15 in board & advisors, 29 in team); the tracked headcount is 134.
| Name | Role | Group |
|---|---|---|
Josh Silva | Head Of Sales Operations | Leadership |
Iman Mohtashemi | Senior Director Data Engineering | Leadership |
Michael F. | Director, Engineering | Leadership |
Yuandan Lou | Senior Director of Software | Leadership |
Taylor Page, Ph.D. | Director, Product Management | Leadership |
Rebecca Rutherford | Sr. Director Of Product Management | Leadership |
James Harland | Senior Director, Technical Operations | Leadership |
Pritam Patil | Associate Director, Production Operations | Leadership |
Eldar Bolsakov | VP, Corporate Controller | Leadership |
Richard Baldwin | VP, Nanoparticle Research Seer | Leadership |
Samuel Lee, CPA, MBA | Director of Accounting | Leadership |
Charles Endweiss | Vice President, Finance & Sales Operations | Leadership |
Theo Platt | Vice President Data Engineering And Software | Leadership |
Andrew Lee | Director, Corporate Strategy | Leadership |
Marissa Dixon | Chief People Officer | Leadership |
Serafim Batzoglou | Chief Data Officer | Leadership |
Omid Farokhzad | Chair & CEO | Leadership |
David R. Horn | President & CFO | Leadership |
Kenny Ross | Chief Operations & Product Officer | Leadership |
Aaron Gajadhar, PhD | Director Strategic Applications | Leadership |
49 more people are available in the full profile.
Complete people profiles for Seer
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Seer
Seer is a publicly listed company on the NASDAQ with ticker symbol SEER in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Dec 2020
- Listed onNASDAQ: SEER
- Listed entitySeer, Inc.
- Exchange sectorHealth technology
- ISINUS81578P1066
- Share price$2.11 (-1.86% on the day) · 2026-10-13
- Market capitalisation$116.8M
- EPS (diluted, trailing year)$-1.22
- Volume (last session)107,897
Financials of Seer
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $16.1M | -$73.6M | -$72.3M |
| 2024 | $13.9M | -$86.6M | -$94.2M |
| 2023 | $15.2M | -$86.3M | -$99.4M |
| 2022 | $14.7M | -$93.0M | -$92.1M |
| 2021 | $6.4M | -$71.2M | -$68.1M |
Detailed financial statements for Seer
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Seer
4 dated milestones of Seer across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Seer is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Series D, of $55.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Seer
Seer has 9 listed competitors in our database, 9 of them funded. They include Metabolon, Cyrus Biotechnology, Maze Therapeutics, Vividion Therapeutics and Alector, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| cyrusbio.com | 2014 | Seattle, United States | $31.99M | 23 | Cloud-based protein-modeling software is developed for drug discovery. | |
| mazetx.com | 2018 | Redwood, United States | $496M | 111 | Genetic biomarkers are developed for neurological, metabolic, and renal diseases. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| tangotx.com | 2017 | Cambridge, United States | $165M | 140 | Novel cancer drugs are developed using synthetic lethality screening. | |
| biognosys.com | 2008 | Schlieren, Switzerland | $9.13M | – | Proteomics services are delivered via discovery and targeted platforms. | |
| neophore.com | 2017 | Cambridge, United Kingdom | $44.56M | 10 | NeoPhore is focused on cancer neoantigen evolution therapies. | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis |
Detailed competitors of Seer
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Seer
The website of Seer (seer.bio) receives about 15.9K visits a month and ranks #1,576,376 among all websites worldwide, #2,105 in Biotechnology and Pharmaceuticals.
- Monthly visits15.9K
▼ 5.9% vs previous month
- Unique visitors7.2K
per month
- Global rank#1,576,376
among all websites
- Category rank#2,105
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.6
- Average visit20 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Seer. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alamarbio.com | 100% | 27.2K | #1,239,400 | View details | |
| parexel.com | 58% | 220.8K | #203,256 | View details |
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Seer (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Seer
Complete news archive for Seer
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seer
Seer was founded in 2017.
Seer is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Seer is a funded company, having raised a total of $127.5M across 7 funding rounds to date. The company's 1st funding round was a Grant of $150K, raised on Jan 2017.
Seer has 134 employees.
Annual revenue of Seer is $16.12M as on Dec 31, 2025.
Seer, Inc. is dedicated to pioneering innovative technologies for proteomics research. The company is engaged in developing tools like the Proteograph Product Suite to enable deep, rapid, and unbiased proteomics at scale. Solutions such as the Proteograph Analysis Suite are provided for efficient data analysis. Operating in the healthcare and biotechnology sectors, Seer aims to eliminate barriers in proteomics, empowering the scientific community to achieve exceptional outcomes. Their technology is utilized by top researchers and featured in numerous scientific publications. The mission is centered on decoding the proteome to improve human health globally.
Seer's top competitors include Alector, Maze Therapeutics and Metabolon.
Seer offers Proteograph Product Suite, Proteograph Analysis Suite, and Seer Technology Access Center.
Yes, Seer is publicly traded on NASDAQ under the ticker symbol SEER.
Seer has 11 investors. Key investors include Fidelity Investments, T. Rowe Price, Bruker, Aju IB Investment, and HBM Healthcare Investments.
Seer operates through Seer, Inc..